Christi M. Terry, Ph.D.

Research Interests

  • Anti-Inflammatory Agents, Antirheumatic Agents, and Inflammation Mediators
  • Adiponectin
  • Soluble Epoxide Hydrolase
  • Adipose Tissue
  • Drug Delivery
  • Hemodialysis Access
  • Magnetic Resonance Imaging - MRI

Languages

  • English

Academic Information

  • Departments: Bioengineering - Adjunct Associate Professor, Internal Medicine - Research Associate Professor, Pharmaceutics and Pharmaceutical Chemistry - Adjunct Associate Professor
  • Divisions: Nephrology

Academic Office Information

  • (801) 557-7747 Ext 5380
  • VA - Building #2
    Nephrology 151 N
    500 S Foothill Dr, Room: GA13
    Salt Lake City, UT 84148

Research Statement

My research focuses on developing novel treatments to improve hemodialysis vascular access function. I also collaborate on studies investigating targeted, localized delivery of drugs to decrease the recurrence of breast cancer.

Academic Bio

Dr. Christi Terry has a Ph.D. in Pharmacology and Toxicology and is a Research Associate Professor in the Division of Nephrology and Hypertension and adjunct faculty in the Department of Pharmaceutics and in the Department of Engineering. Her research focus is to promote the function of hemodialysis vascular accesses. To that end, she investigates novel means of drug delivery to vascular accesses. Drugs of interest include FDA-approved drugs such as imatinib (Gleevec), sunitinib (Sutent) and sirolimus (Rapamune), glitazones (Pioglitazone and Rosiglitazone) and rilonacept (a IL-1 blocker), but also other novel drugs such as inhibitors of soluble epoxide hydrolase. She investigates the use of synthetic polymer vascular wraps and hydrogels as well as native adipose (fat) tissue to deliver drugs. Dr. Terry has particular interest in the adipose-tissue derived protein adiponectin and participates in both basic research studies and clinical studies on the role this protein plays in hemodialysis patient health and hemodialysis access function.

Dr. Terry also studies, in collaboration with bio-engineers and biomedical physicists, the effect of blood flow parameters on vascular access function. For such studies she uses magnetic resonance imaging (MRI) to obtain high-resolution pictures of the blood vessels and to obtain volumetric blood flow rates. This data is then used for computational fluid dynamic (CFD) modeling to yield wall shear stress profiles and other hemodynamic parameters.

Dr. Terry also is interested in developing nerve guide conduits for the delivery of drugs that could enhance nerve regeneration. For these studies, she collaborates with reconstructive surgeons and bioengineers.

She performs wet lab experiments as well as clinical investigations with patients, collaborating with basic scientists and clinicians both at the University of Utah and other institutions. Dr. Terry enjoys working with graduate students and undergraduates to help them learn scientific techniques and principles. She is a member of the American Society of Nephrology.

Education History

Type School Degree
Postdoctoral Training University of Utah, Department of Internal Medicine
Nephrology and Hypertension
Postdoctoral Training
Research Fellow University of Utah
National Research Service Award Fellow
Research Fellow
Postdoctoral Training University of Utah
Human Molecular Biology and Genetics
Postdoctoral Training
Doctoral Training University of Utah
Pharmacology and Toxicology
D.Phil.
Undergraduate Mesa State College
Biology
B.S.

Selected Publications

Journal Article

  1. Terry CM, He Y, Cheung AK (Summer, 2016). Rivaroxaban improves patency and decreases inflammation in a mouse model of catheter thrombosis. Thromb Res, 144, 106-112.
  2. Dember LM, Imrey PB, Duess MA, Hamburg NM, Larive B, Radeva M, Himmelfarb J, Kraiss LW, Kusek JW, Roy-Chaudhury P, Terry CM, Vazquez MA, Vongpatanasin W, Beck GJ, Vita JA, Hemodialysis Fistula Maturation Study (Summer, 2016). Vascular Function at Baseline in the Hemodialysis Fistula Maturation Study. J Am Heart Assoc, 5(7).
  3. Kwon SH, Li L, He Y, Tey CS, Li H, Zhuplatov I, Kim SJ, Terry CM, Blumenthal DK, Shiu YT, Cheung AK (Winter 2016). Prevention of venous neointimal hyperplasia by a multi-target receptor tyrosine kinase inhibitor. J Vasc Res, 52(4), 244-56.
  4. Allon M, Greene T, Dember LM, Vita JA, Cheung AK, Hamburg NM, Imrey PB, Kaufman JS, Robbin ML, Shiu YT, Terry CM, Umphrey HR, Feldman HI and The Hemodialysis Fistula Maturation Group (spring, 2016). Association between preoperative vascular function and postoperative arteriovenous fistula development. J Am Soc Nephrol, 27.
  5. Terry CM, Zhuplatov I, He Y, Wun TC, Kim SE, Cheung AK (Fall, 2015). Assessment of Novel Anti-thrombotic Fusion Proteins for Inhibition of Stenosis in a Porcine Model of Arteriovenous Graft. PLoS ONE, 10(9), e0137381.
  6. Terry CM, Carlson ML, He Y, Ulu A, Morisseau C, Blumethal DK, Hammock BD, Cheung AK (2014). Aberrant soluble epoxide hydrolase and oxylipin levels in a porcine arteriovenous graft stenosis model. J Vasc Res, 51(4), 269-282.
  7. Terry CM, Dember LM (2013). Novel therapies for hemodialysis vascular access dysfunction: myth or reality? Clin J Am Soc Nephrol, 8(12), 2202-2212.
  8. Serial analysis of lumen geometry and hemodynamics in human arteriovenous fistula for hemodialysis using magnetic resonance imaging and computational fluid dynamics.He Y, Terry CM, Nguyen C, Berceli SA, Shiu YT, Cheung AK (2013). Serial analysis of lumen geometry and hemodynamics in human arteriovenous fistula for hemodialysis using magnetic resonance imaging and computational fluid dynamics. J Biomech, 46(1), 165-9.
  9. Soluble epoxide hydrolase expression in a porcine model of arteriovenous graft stenosis and anti-inflammatory effects of a soluble epoxide hydrolase inhibitor.Sanders WG, Morisseau C, Hammock BD, Cheung AK, Terry CM (2012). Soluble epoxide hydrolase expression in a porcine model of arteriovenous graft stenosis and anti-inflammatory effects of a soluble epoxide hydrolase inhibitor. Am J Physiol Cell Physiol, 303(3), C278-90.
  10. A biodegradable perivascular wrap for controlled, local and directed drug delivery.Sanders WG, Hogrebe PC, Grainger DW, Cheung AK, Terry CM (2012). A biodegradable perivascular wrap for controlled, local and directed drug delivery. J Control Release, 161(1), 81-9.
  11. Sanders WG, morisseau C, Hammock BD, Cheung AK, Terry CM (2012). Soluble Epoxide Hydrolase Expression in a Porcine Model of Arteriovenous Graft Stenosis and Anti-Inflammatory Effects of a Pharmacological Inhibitor of Soluble Epoxide Hydrolase. Am J Physiol Cell Physiol, 303(3), C278-90.
  12. Terry CM, Li L, Li H, Zhuplatov I, Blumenthal DK, Kim SE, Owen SC, Kholmovski EG, Fowers KD, Rathi R, Cheung AK (2012). In vivo evaluation of the delivery and efficacy of a sirolimus-laden polymer gel for inhibition of hyperplasia in a porcine model of arteriovenous hemodialysis graft stenosis. http://www.sciencedirect.com/science/article/pii/S0168365912001976?v=s5. J Control Release, 160(3), 459-67.
  13. Li L, Blumenthal DK, Terry CM, He Y, Carlson ML, Cheung AK (Jan. 2011). PDGF-induced proliferation in human arterial and venous smooth muscle cells: molecular basis for differential effects of PDGF isoforms. J Cell Biochem, 12(1), 289-298.
  14. Owen SC, Li H, Sanders WG, Cheung AK, Terry CM (2010). Correlation of tissue drug concentrations with in vivo magnetic resonance images of polymer drug depot around arteriovenous graft. J Control Release, 146(1), 23-30.
  15. Terry CM, Kim SE, Li L, Goodrich KC, Hadley JR, Blumenthal DK, Parker DL, Cheung AK (2009). Longitudinal assessment of hyperplasia using magnetic resonance imaging without contrast in a porcine arteriovenous graft model. Acad Radiol, 16(1), 96-107.
  16. Preston JS, Tasdizen T, Terry CM, Cheung AK, Kirby RM (2009). Using the stochastic collocation method for the uncertainty quantification of drug concentration due to depot shape variability. IEEE Trans Biomed Eng, 56(3), 609-620.
  17. Li L, Terry CM, Shiu YT, Cheung AK (2008). Neointimal hyperplasia associated with synthetic hemodialysis grafts.. Kidney Int, 74(10), 1247-61.
  18. Li L, Terry CM, Blumenthal DK, Kuji T, Masaki T, Kwan BC, Zhuplatov I, Leypoldt JK, Cheung AK (2007). Cellular and morphological changes during neointimal hyperplasia development in a porcine arteriovenous graft model. Nephrol Dial Transplant, 22(11), 3139-46.
  19. Terry CM, Blumenthal DK, Sikharam S, Li L, Kuji T, Kern SE, Cheung AK (2006). Evaluation of histological techniques for quantifying haemodialysis arteriovenous (AV) graft hyperplasia. Nephrol Dial Transplant, 21(11), 3172-9.
  20. Li L, Blumenthal DK, Masaki T, Terry CM, Cheung AK (2006). Differential effects of imatinib on PDGF-induced proliferation and PDGF receptor signaling in human arterial and venous smooth muscle cells. J Cell Biochem, 99(6), 1553-1563.
  21. Kuji T, Masaki T, Goteti K, Li L, Zhuplatov S, Terry CM, Zhu W, Leypoldt JK, Rathi R, Blumenthal DK, Kern SE, Cheung AK (2006). Efficacy of local dipyridamole therapy in a porcine model of arteriovenous graft stenosis. Kidney International, 69(12), 2179-2185.
  22. Terry CM, Kling SJ, Cheang KI, Hoidal JR, Rodgers GM (2004). Polymorphisms in the 5'-UTR of the tissue factor gene are associated with altered expression in human endothelial cells. J Thromb Haemost, 2(8), 1351-8.
  23. Terry CM, Clikeman JA, Hoidal JR, Callahan KS (1999). TNF and IL-1 induce heme oxygenase-1 via protein kinase C, calcium and phospholipase A2 in endothelial cells. Am J Physiol, 276 (5part2), H1493-H1501.
  24. Terry CM, Clikeman JA, Hoidal JR, Callahan KS (1998). Effect of tumor necrosis factor and interleukin-1 on heme oxygenase-1 expression in human endothelial cells. Am J Physiol, 274 (3part2), H883-H891.
  25. Terry CM, Callahan KS (1996). Protein Kinase C regulates cytokine-induced tissue factor transcription and procoagulant activity in human endothelial cells. Journal of Laboratory and Clinical Medicine, 127, 81-93.
  26. Nichols WK, Terry CM, Cutler NS, Appleton ML, Jesthi PK, Yost GS (1995). Oxidation at C-1 controls the cytotcoxicity of 1, 1-dichloro-2, 2-bis (p-chlorophenyl)ethane by rabbit and human lungs. Drug Metabolism and Disposition, 23(5), 595-599.
  27. Georges M, Gunawardana A, Threadgill D, Lathrop M, Olsaker I, Mishra A, Sargeant L, Schoeberlein A, Steele M, Terry CM, Zhao X, Holm T, Fries R, Womack J (1991). Characterization of a set of variable number tandem repeat markers conserved in Bovidae. Genomics, 11 (1), 24-32.